Eli Lilly and Co.

Life sciences panel pegs bright spots in IndianaRestricted Content

August 14, 2010
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
More

Eli Lilly loses patent lawsuit for Strattera

August 13, 2010
 IBJ Staff and Associated Press
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
More

For Lilly, it's a big one that got away

August 11, 2010
J.K. Wall
An experimental medicine for hepatitis C that Lilly helped identify and develop is now on the cusp of market approval, with analysts predicting as much as $2 billion in annual U.S. sales.
More

Court defeat lost in Lilly's gloomy long-term outlook

August 9, 2010
J.K. Wall
Eli Lilly and Co.'s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn from investors, who have shunned the stock because of five looming patent expirations.
More

Lilly among bidders for Denmark company, source says

July 30, 2010
Bloomberg News
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said. Ascendis may choose a final bidder by early September.
More

Lilly loses appeal over patent for cancer drug Gemzar

July 28, 2010
 IBJ Staff and Bloomberg News
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013. Gemzar generated $1.36 billion in global sales in 2009.
More

Lilly's second-quarter profits surge 16 percent

July 22, 2010
J.K. Wall
Indianapolis-based drugmaker Eli Lilly and Co. recorded profits of $1.3 billion, or $1.22 per share, during the three months ended June 30, even after paying $27 million in severance to laid off employees.
More

Lilly completes $180 million acquisition of Alnara

July 21, 2010
Massachusetts-based Alnara Pharmaceuticals Inc. is a privately held company developing an enzyme-replacement therapy for disorders of the pancreas.
More

New rules raise stakes for Lilly drug

July 21, 2010
J.K. Wall
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses of the disease.
More

Lilly reveals plans to cut 340 IT jobs

July 15, 2010
J.K. Wall
The Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and some cuts. Another 115 cuts will be made this month, and the remainder by the end of the year.
More

Lilly, Roche dive deep into diagnostics

July 14, 2010
J.K. Wall
Two Indianapolis giants—Eli Lilly and Co. and Roche Diagnostics—are working hard to pair up drugs and diagnostic tests to gin up more sales.
More

Lilly's Alzheimer's gamble takes aim at $10 billion in patent losses

July 13, 2010
Bloomberg News
Both of Lilly's late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers to be a main contributor to Alzheimer's. A drug that stops or reduces memory loss caused by Alzheimer's may be worth more than $5 billion a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
More

Lilly to cut 170 manufacturing jobs by year's end

July 12, 2010
J.K. Wall
Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling drugs.
More

Diagnostics division to help Lilly tailor treatmentsRestricted Content

July 10, 2010
J.K. Wall
Eli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit from a Lilly drug.
More

Lilly's Lechleiter: No change in plans

July 7, 2010
J.K. Wall
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no mega-merger.
More

Men on Viagra, Cialis show triple rate of sex diseases in study

July 6, 2010
 IBJ Staff and Bloomberg News
The findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly's Cialis, may be more likely to engage in unsafe sex than nonusers.
More

Lilly acquires biotech company with pancreatic drug

July 2, 2010
J.K. Wall
Massachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years, recently submitted its drug to the FDA for market approval.
More

Grassley asks Lilly, peers about whistleblower treatment

July 1, 2010
Bloomberg News
U.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal how they treat whistleblowers who file complaints under the False Claims Act.
More

Lilly's Effient steps forward, then back

June 30, 2010
J.K. Wall
A day after doctors were alerted to a black-box warning that could slow sales of Effient’s main competitor, Plavix, a medical journal published research showing that patients suffered 43-percent more cancer tumors on Effient than on Plavix.
More

Marcadia enlists Lilly to help develop new diabetes drug

June 28, 2010
J.K. Wall
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s current Glucagon for patients with severe hypoglycemia.
More

Hoosier firms that rely on innovation pine for patent reform

June 26, 2010
J.K. Wall
One key change would grant patents to the first inventor to file an application, not the first who can prove to have made the invention first.
More

Lilly layoffs pare communications department

June 21, 2010
J.K. Wall
The giant drugmaker is in the process of trimming 35 percent—or about 19 people—from its 55-person communications staff. Most of that staff is based in Indianapolis.
More

Recession hammered revenue of Indiana's largest public companies

June 19, 2010
Marc D. Allan
Few escaped the Great Recession unscathed, and unusual circumstances helped some appear as though they did.
More

Slow economy bruises profits of Indiana's largest public companiesRestricted Content

June 19, 2010
Marc D. Allan
One-time events influenced bottom lines of some of the few companies that made more money in 2009.
More

Lilly, Amylin stock rises on drug postponement

June 18, 2010
 IBJ Staff and Bloomberg News
Roche Holding AG's decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals Inc. and drug partner Eli Lilly and Co.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am a Lyft driver who is a licensed CDL professional driver. ALL Lyft drivers take pride in providing quality service to the Indianapolis and surrounding areas, and we take the safety of our passengers and the public seriously.(passengers are required to put seat belts on when they get in our cars) We do go through background checks, driving records are checked as are the personal cars we drive, (these are OUR private cars we use) Unlike taxi cabs and their drivers Lyft (and yes Uber) provide passengers with a clean car inside and out, a friendly and courteous driver, and who is dressed appropriately and is groomed appropriately. I go so far as to offer mints, candy and/or small bottle of water to the my customers. It's a mutual respect between driver and passenger. With Best Regards

  2. to be the big fish in the little pond of IRL midwest racin' when yer up against Racin' Gardner

  3. In the first sentance "As a resident of one of these new Carmel Apartments the issue the local governments need to discuss are build quality & price." need a way to edit

  4. As a resident of one of these new Carmel Apartments the issue the local governments need to discuss is build quality & price. First none of these places is worth $1100 for a one bedroom. Downtown Carmel or Keystone at the Crossing in Indy. It doesn't matter. All require you to get in your car to get just about anywhere you need to go. I'm in one of the Carmel apartments now where after just 2.5 short years one of the kitchen cabinet doors is crooked and lawn and property maintenance seems to be lacking my old Indianapolis apartment which cost $300 less. This is one of the new star apartments. As they keep building throughout the area "deals" will start popping up creating shoppers. If your property is falling apart after year 3 what will it look like after year 5 or 10??? Why would one stay here if they could move to a new Broad Ripple in 2 to 3 years or another part of the Far Northside?? The complexes aren't going to let the "poor" move in without local permission so that's not that problem, but it the occupancy rate drops suddenly because the "Young" people moved back to Indy then look out.

  5. Why are you so concerned about Ace hardware? I don't understand why anyone goes there! Every time ive gone in the past, they don't have what I need and I end up going to the big box stores. I understand the service aspect and that they try to be helpful but if they are going to survive I think they might need to carry more specialty parts.

ADVERTISEMENT